Liposomal Drugs Should Not Be Compounded – Until Technology Catches Up
Executive Summary
US FDA’s Pharmacy Compounding Advisory Committee agrees with AbbVie that liposomal drugs and products using hot melt extrusion should be listed as prohibited from compounding – but the panel also hopes to see technology advance to change that conclusion.